Baird Financial Group
ALXN

Baird Financial Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Baird Financial Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,434
Closed -$447K – 1949
2021
Q2 		$447K Sell
2,434
-120
-5% -$20.6K ﹤0.01% 1436
2021
Q1 		$391K Sell
2,554
-845
-25% -$131K ﹤0.01% 1427
2020
Q4 		$531K Sell
3,399
-62
-2% -$7.97K ﹤0.01% 1217
2020
Q3 		$396K Sell
3,461
-5
-0.1% -$539 ﹤0.01% 1230
2020
Q2 		$389K Sell
3,466
-241
-7% -$25.6K ﹤0.01% 1213
2020
Q1 		$333K Sell
3,707
-346,398
-99% -$34M ﹤0.01% 1181
2019
Q4 		$37.9M Sell
350,105
-21,386
-6% -$2.29M 0.14% 182
2019
Q3 		$36.4M Sell
371,491
-1,045
-0.3% -$118K 0.14% 176
2019
Q2 		$48.8M Sell
372,536
-1,937
-0.5% -$250K 0.19% 136
2019
Q1 		$50.6M Buy
374,473
+21,143
+6% +$2.63M 0.3% 97
2018
Q4 		$34.4M Buy
353,330
+2,745
+0.8% +$324K 0.23% 122
2018
Q3 		$48.1M Buy
350,585
+91,791
+35% +$11.5M 0.3% 95
2018
Q2 		$32.1M Buy
258,794
+229,676
+789% +$26.8M 0.22% 132
2018
Q1 		$3.25M Buy
29,118
+3,056
+12% +$365K 0.02% 516
2017
Q4 		$3.12M Buy
26,062
+455
+2% +$55.4K 0.02% 515
2017
Q3 		$3.59M Buy
25,607
+1,228
+5% +$167K 0.03% 483
2017
Q2 		$2.97M Buy
24,379
+9,773
+67% +$1.14M 0.02% 514
2017
Q1 		$1.77M Buy
14,606
+10,028
+219% +$1.29M 0.01% 626
2016
Q4 		$560K Sell
4,578
-7,867
-63% -$963K ﹤0.01% 895
2016
Q3 		$1.52M Sell
12,445
-8,366
-40% -$1.08M 0.01% 631
2016
Q2 		$2.43M Buy
20,811
+145
+0.7% +$20.6K 0.02% 512
2016
Q1 		$2.88M Sell
20,666
-2,863
-12% -$420K 0.03% 464
2015
Q4 		$4.49M Sell
23,529
-9,509
-29% -$1.66M 0.04% 367
2015
Q3 		$5.17M Buy
33,038
+139
+0.4% +$25.4K 0.05% 319
2015
Q2 		$5.95M Buy
+32,899
New +$5.68M 0.06% 301

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Baird Financial Group's ALXN Position: Q3 2021 in Review

Baird Financial Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,434 shares — an estimated $447K sold.

Baird Financial Group first reported a position in ALXN in Q2 2015 and held it in 25 quarters. The position peaked at $50.6M in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Baird Financial Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Baird Financial Group sold 2,434 Alexion Pharmaceuticals shares in Q3 2021, an estimated $447K.
  • Baird Financial Group first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 25 quarters.
  • Baird Financial Group's Alexion Pharmaceuticals position peaked at $50.6M in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Baird Financial Group's 13F filing for Q3 2021, filed 12 Nov 2021.